Harbin Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Habin Pharmaceutical Group") is a Sino-foreign joint venture and owns two listed companies, Harbin Pharmaceutical Co., Ltd. and Renmin Tongtai. The group owns the Harbin Pharmaceutical General Factory, Harbin Pharmaceutical Three Essences, Harbin Pharmaceutical Sixth Factory, Harbin Pharmaceutical Two Chinese Medicine Factory, Harbin Pharmaceutical Shiyitang, Harbin Pharmaceutical Biology, Harbin Pharmaceutical Three Essences Factory, Harbin Pharmaceutical Three Essences Factory, Harbin Pharmaceutical Three Essences, Harbin Pharmaceutical Three Es 11 industrial enterprises including He, Harbin Pharmaceutical Sanjing Children, Harbin Pharmaceutical Vaccine, and 2 commercial distribution enterprises and 1 drug research institute, Harbin Pharmaceutical People's Tongtai and Harbin Pharmaceutical Marketing Co., Ltd.

The group's main business covers six major business segments: antibiotics, over-the-counter drugs and health products, traditional and modern Chinese medicine, biomedicine, animal vaccines and pharmaceutical business. Harbin Pharmaceutical Co., Ltd. has 1,816 drug approvals and 74 health food approvals. The leading products include calcium gluconate oral solution, zinc gluconate oral solution, amoxicillin capsules, Shuanghuanglian oral solution, prostadil injection, pediatric aminophen Huangnamin granules, lacidipine tablets, and ceftiam hydrochloride for injection , ibuprofen granules, new gay Zhonggai brand high calcium tablets, etc. As of the end of 2018, it has annually produced 2,200 tons of raw materials, 980 million chemical injections, 180 million traditional Chinese medicine injections, 2 billion oral liquids, 12 billion tablets, 13.1 billion capsules, and 1.2 billion bags of chemical granules. Production capacity.

In 2018, the group had 8 varieties with sales revenue of over 100 million yuan, and had five trademarks of "Hayi Medicine", "Three Essences", "Guizhonggu", "Hutong", "Shiyitang" and "Shiyitang" and the use of "Shiyitang". right. Rentongtai, the listed company, mainly engaged in pharmaceutical wholesale and retail businesses, covering more than 10,000 product specifications, including Chinese patent medicines, Chinese herbal medicines, chemical preparations, antibiotics, biological products, biochemical drugs, medical devices and health products. There are 314 Renmin Tongtai Pharmaceutical chain stores with an annual turnover of 1.15 billion yuan. Its drug wholesale enterprises have carried out close cooperation with more than 1,000 medical institutions, more than 1,900 third terminals, and nearly 700 commercial customers in Heilongjiang Province. The market coverage rate of third-level hospitals is more than 95%, and the market coverage of second-level hospitals is more than 2-level hospitals. The rate is more than 90%. Its logistics and distribution center is the first modern medical flow center in Heilongjiang Province and a larger Northeast region. Its storage capacity is 400,000 boxes and an annual throughput capacity of 30 billion yuan.

The Group also has a new drug research and development base covering an area of ​​40,000 square meters and a building area of ​​38,000 square meters - Harbin Pharmaceutical Group Technology Center, which has five research and developments, including biopharmaceuticals, chemical raw materials, chemical preparations, health foods, and quality testing and analysis. The platform has 25 invention authorized patents, and has obtained 6 production approvals and 17 clinical approvals in the past five years.